New Findings on the Combination of Rybrevant and Lazartinib Reported at WCLC 2026

Insights from the COPERNICUS Trial at WCLC 2026

In a groundbreaking announcement on September 14, 2026, Johnson & Johnson revealed new insights from the Phase IIb COPERNICUS trial regarding the combination of Rybrevant® and Lazartinib® (the active substances being amivantamab and lazartinib, respectively) for the treatment of untreated advanced non-small cell lung cancer (NSCLC) with common EGFR mutations.

Key Findings

The findings suggest that utilizing a preventive supportive therapy alongside a reduced dosing schedule can significantly enhance the treatment experience for patients. In particular, the data presented at the World Conference on Lung Cancer (WCLC) 2026 demonstrated that cumulative rates of treatment-related adverse events—such as rashes, thromboembolic events, and infusion-related reactions—remained notably low. Specifically, less than 1% of the patients discontinued treatment due to these adverse events during a year-long period.

Moreover, the evidence provided by the COPERNICUS trial reinforces the survival benefits indicated in the MARIPOSA trial, further supporting the use of Rybrevant combined with Lazartinib as a primary treatment option for patients with EGFR mutations. The trial aims to reflect real-world clinical settings with patient demographics that span various racial and ethnic groups, which enhances the applicability of the results across a broader patient population.

Detailed Analysis of the COPERNICUS Trial

The COPERNICUS trial included a diverse patient population, with significant representation from underrepresented groups. Key metrics of safety were evaluated along with the primary endpoint focusing on progression-free survival (PFS). As per the latest results, the trial has enrolled 300 patients, with an average age of 67. 22% of participants were aged 75 and older, highlighting the trial's considerations for older patients who are significantly impacted by lung cancer treatment.

The preliminary outcomes of 214 patients undergoing the therapy demonstrated that the majority of adverse events were graded 1 or 2. Specifically, a reported 25% experienced rashes, while adverse reactions related to the treatment and incidences of venous thromboembolism (VTE) remained low at 3% each. Importantly, no patients discontinued due to adverse treatment reactions.

These results stand in contrast to those from the Phase III MARIPOSA trial, where a higher incidence of rashes and VTE was observed among patients treated with osimertinib, further suggesting the potential advantage of Rybrevant and Lazartinib’s therapeutic regimen. This aligns with a growing body of evidence indicating that dual targeting of EGFR and MET can lead to better patient outcomes.

Comments from Experts

Dr. Balazs Halmos, a leading oncologist from Montefiore Einstein Comprehensive Cancer Center, commented on the significance of these findings, stating that the combination of Rybrevant and Lazartinib not only holds the potential to extend survival in EGFR mutation-positive lung cancer patients but also marks a substantial advancement in treatment strategies. The incorporation of subcutaneous administration and preventive measures is designed to enhance the patient’s overall treatment experience, enabling better adherence and continuity of therapy.

Dr. Yusri Elsayed, the Global Head of Oncology at Johnson & Johnson, emphasized the ongoing evolution of their approach to treating EGFR mutation-positive lung cancer through the opportunities presented by emerging evidence. The COPERNICUS trial exemplifies the company's commitment to aligning clinical development with real-world experiences, aiming to deliver meaningful changes to patients at every stage of their treatment journey.

Conclusion

Johnson & Johnson's findings presented at WCLC 2026 reflect a significant step towards optimizing treatment paradigms for NSCLC by incorporating a combination of innovative therapies and supportive strategies. As research continues, it will further elucidate the potential benefits and enhance our understanding of effective lung cancer management. This aligns with the overarching mission to provide tailored healthcare solutions aimed at improving patient outcomes worldwide.